Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

NCT05912621 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Overweight and Obesity
Overweight

Interventions

DRUG: Tirzepatide

Sponsor

Stanford University

Collaborators

[object Object]